MECP2 and Rett syndrome: Given that RTT is a monogenic disorder caused by loss of function mutations in MECP2 and that its protein has crucial roles in several physiological pathways, gene delivery of a wild copy of MECP2 to mutant brain cells have been widely contemplated for the treatment of RTT.